Coronavirus company news summary – Vexos to provide 10,000 MVM Ventilators to Canada – FDA provides 510(k) clearance to Philips Biosensor BX100

27 May 2020 (Last Updated May 27th, 2020 09:29)

GenScript Biotech Europe BV has received CE marking for its in vitro diagnostic SARS-CoV-2 diagnostic product, the cPass SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit. The kit is deigned to identify the presence of Covid-19 neutralising antibodies in one hour. It does not need live biological materials or biosafety containment.

Vexos has announced that it will manufacture 10,000 Mechanical Ventilator Milano (MVM) units for distribution across Canada. These units will aid in the country’s fight against Covid-19. The ventilator was developed by the International MVM Group to address the requirements for the care and recovery for of seriously affected Covid-19 patients. Deliveries of the units are expected to start in July.

US Food and Drug Administration (FDA) has provided the 510(k) clearance to Royal Philips for its wearable biosensor (Philips Biosensor BX100) for Covid-19 patient management. The biosensor improves clinical observation of patient deterioration detection, to aid in detecting the risk and help clinicians with early interventions. The technology also received the CE Mark.

Prime Home Health Services has introduced at-home monitoring of Covid-19 patients remotely using technology from MonitorMe. This technology provides contactless monitoring of patients, which reduces the contact between health care workers and patients and decreases the burden on hospitals and nursing homes.